Cullinan Management’s Promising Position in Healthcare: Buy Rating Supported by Strong Phase 2b Data and Strategic Developments

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Cullinan Management (CGEM – Research Report), with a price target of $34.00.

Soumit Roy has given his Buy rating due to a combination of factors that highlight Cullinan Management’s promising position in the healthcare sector. The company’s Phase 2b data for zipalertinib in treating 2L/2L+ NSCLC with EGFR ex20ins mutations is considered best in class, demonstrating a notable overall response rate and median duration of response in a challenging patient group. The oral administration and reduced toxicity of zipalertinib compared to existing treatments like Rybrevant further enhance its appeal.
Despite potential competition from upcoming FDA-approved treatments, zipalertinib’s systemic efficacy, particularly in patients with brain metastases, supports its use following Rybrevant therapy. Although questions remain about its CNS activity, upcoming data from the Phase 2 REZILIENT2 study is expected to provide further insights. The company’s strong cash position and strategic developments also contribute to the positive outlook, justifying the Buy rating.